ASIT biotech announces the approval by the regulatory authorities of a follow-up study of the Phase I/IIa clinical trial with its hdm-ASIT+TM product candidate for house dust mite rhinitis
(WorldNews Belgium)

ASIT biotech announces the approval by the regulatory authorities of a follow-up study of the Phase I/IIa clinical trial with its hdm-ASIT+TM product candidate for house dust mite rhinitis A subset of patients treated during the Phase I/IIa clinical trial with its hdm-ASIT+TM product candidate for house dust mite rhinitis will undergo a complementary medical visit to assess potential long-term effect of hdm-ASIT+TM Brussels, Belgium, 16 August 2017, 5.45 pm (CEST) - ASIT biotech (Euronext: ASIT - BE0974289218), a Belgian clinical-stage biopharmaceutical company focused on the research, development and future commercialization of breakthrough immunotherapy products for the treatment of...